Alumis Inc. Raises $345.1M in Public Offering, Significant Dilution Expected
ALMS has more than doubled off its 52-week low of $2.76 on elevated volume (4.3× avg).
Summary
Alumis Inc. announced a public offering of 20.3 million shares at $17.00 per share, raising approximately $345.1 million, which represents substantial dilution for existing shareholders.
Key Events · Financing and Capital Events · ALMS
-
Public Offering Announced
Alumis Inc. entered into an underwriting agreement for a public offering of 17,650,000 shares of common stock.
-
Underwriters' Option Exercised
The underwriters fully exercised their option to purchase an additional 2,647,500 shares, bringing the total offering to 20,297,500 shares.
-
Gross Proceeds
The offering is expected to generate gross proceeds of approximately $345.1 million for the company.
-
Offering Price
Shares were priced at $17.00 per share, a discount to the current market price of $18.39.
Analysis · ALMS · Life Sciences
Alumis Inc. announced a substantial public offering of 20,297,500 shares of common stock, including the full exercise of the underwriters' option, at a price of $17.00 per share. This offering is expected to generate gross proceeds of approximately $345.1 million for the company. While securing significant capital to extend its financial runway, the offering represents considerable dilution for existing shareholders. The offering price of $17.00 per share is at a discount compared to the current market price of $18.39. This capital raise follows the company's preliminary unaudited cash, cash equivalents, and marketable securities balance of approximately $308.6 million as of December 31, 2025.
At the time of this filing, ALMS was trading at $18.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $2.76 to $22.30. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.